81.88
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$78.39
Aprire:
$78.27
Volume 24 ore:
1.90M
Relative Volume:
0.83
Capitalizzazione di mercato:
$12.42B
Reddito:
$4.39B
Utile/perdita netta:
$-1.58B
Rapporto P/E:
-8.2209
EPS:
-9.96
Flusso di cassa netto:
$546.00M
1 W Prestazione:
-1.15%
1M Prestazione:
-7.73%
6M Prestazione:
-41.10%
1 anno Prestazione:
-36.29%
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Confronta ILMN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ILMN
Illumina Inc
|
81.88 | 12.42B | 4.39B | -1.58B | 546.00M | -9.96 |
![]()
TMO
Thermo Fisher Scientific Inc
|
489.06 | 182.21B | 42.88B | 6.34B | 7.27B | 16.53 |
![]()
DHR
Danaher Corp
|
205.16 | 143.37B | 23.88B | 3.90B | 5.30B | 5.28 |
![]()
IDXX
Idexx Laboratories Inc
|
426.25 | 33.92B | 3.90B | 887.87M | 798.08M | 10.67 |
![]()
A
Agilent Technologies Inc
|
115.99 | 33.08B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
174.37 | 30.19B | 15.41B | 1.37B | 2.11B | 7.50 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-04 | Reiterato | Citigroup | Neutral |
2025-02-28 | Downgrade | HSBC Securities | Buy → Hold |
2025-02-10 | Downgrade | Barclays | Equal Weight → Underweight |
2025-02-07 | Downgrade | TD Cowen | Buy → Hold |
2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
2024-11-12 | Ripresa | Morgan Stanley | Equal-Weight |
2024-10-17 | Aggiornamento | HSBC Securities | Hold → Buy |
2024-08-28 | Aggiornamento | Argus | Hold → Buy |
2024-08-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
2024-08-14 | Aggiornamento | Barclays | Underweight → Equal Weight |
2024-08-14 | Aggiornamento | TD Cowen | Hold → Buy |
2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
2024-06-03 | Ripresa | Jefferies | Hold |
2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
2023-12-14 | Iniziato | Guggenheim | Buy |
2023-12-14 | Iniziato | Stephens | Overweight |
2023-12-13 | Iniziato | Wolfe Research | Outperform |
2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
2023-09-28 | Iniziato | Bernstein | Underperform |
2023-07-05 | Ripresa | JP Morgan | Neutral |
2023-01-25 | Downgrade | Argus | Buy → Hold |
2023-01-05 | Iniziato | Scotiabank | Sector Perform |
2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
2022-08-25 | Iniziato | Credit Suisse | Neutral |
2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
2022-01-06 | Ripresa | Piper Sandler | Overweight |
2021-10-15 | Ripresa | Cowen | Outperform |
2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
2021-03-03 | Iniziato | Barclays | Underweight |
2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
2020-09-30 | Iniziato | Atlantic Equities | Overweight |
2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2020-09-22 | Downgrade | Stifel | Buy → Hold |
2020-09-22 | Downgrade | UBS | Buy → Neutral |
2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
2020-01-08 | Iniziato | Wells Fargo | Underweight |
2020-01-07 | Iniziato | Citigroup | Buy |
2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
2019-11-15 | Iniziato | Stifel | Buy |
2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
How Illumina employees step up, reach out, and give back - Illumina
Characterizing alveolar dysregulation in pulmonary fibrosis using Illumina Spatial Technology - Illumina
Personalized Medicine Market Growth Trends 2025-2033: Transition to Customized Medical Care, Developments in Bioinformatics and Genomics, Growing Prevalence of Chronic Diseases - GlobeNewswire Inc.
Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today - Benzinga
Argus cuts Illumina target, sees buying opportunity - Yahoo Finance
Illumina careers: Expanding access to NGS in emerging markets - Illumina
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Nasdaq
Corvex’s Meister joins the board at Illumina. Here’s how he can create value for shareholders - MSN
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Artisan Partners Limited Partnership - MarketBeat
Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders - NBC Los Angeles
Illumina stock hits 52-week low at $80.18 amid market challenges By Investing.com - Investing.com South Africa
Illumina stock hits 52-week low at $80.18 amid market challenges - Investing.com India
New in the lab: Test driving the MiSeq i100 Plus - Illumina
Analyst recommendations: Illumina, Boeing, Next, Walmart, Applovin.... - MarketScreener
AI In Genomics Market to Reach $9.8 Billion, Globally, by 2031 - openPR
NGS Sample Preparation Market Techniques Reshaping Genomic - openPR
Cathie Wood’s ARK trims Illumina, exits Repare Therapeutics stock By Investing.com - Investing.com South Africa
Cathie Wood’s ARK trims Illumina, exits Repare Therapeutics stock - Investing.com
Illumina Adds Activist to Board, Names Former FDA Chief as Chair - MSN
May 9th Options Now Available For Illumina (ILMN) - Nasdaq
Is Illumina Undervalued After An 83% Drop In Its Stock Price? (NASDAQ:ILMN) - Seeking Alpha
Illumina is Now Oversold (ILMN) - Nasdaq
Canaccord maintains Illumina stock hold with $115 target By Investing.com - Investing.com UK
Activist investor Keith Meister to join Illumina's board - Reuters
Activist Investors Seize More Control of Illumina Amid Weakness - Markets Insider
Canaccord holds Illumina stock with $115 target amid board changes By Investing.com - Investing.com UK
Cintas, UPS, Illumina: Market Minute - Yahoo Finance
Illumina rises after board revamp - MSN
Illumina stock rises after board revamp (ILMN:NASDAQ) - Seeking Alpha
Activist Investor Meister to Join Illumina’s Board - WSJ
Activist investor Keith Meister to join Illumina’s board, WSJ reports - 1470 & 100.3 WMBD
Illumina Names Scott Gottlied as Non-Executive Board Chair; Corvex's Keith Meister Joins Board - MarketScreener
Illumina Board Of Directors Elects Dr. Scott Gottlieb Chair, Keith Meister To Join Board Of Directors - MarketScreener
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors - PR Newswire
Activist investor Keith Meister to join Illumina's board, WSJ reports - MSN
Illumina shares rise on WSJ report activist investor Meister will join board By Investing.com - Investing.com UK
Activist investor Meister to join Illumina's board, WSJ reports - MarketScreener
Activist Investor Keith Meister Will Join The Board Of Directors Of Illumina- WSJ - MarketScreener
Single Cell Genome Sequencing Market Detailed In New Research - openPR
High End Cellomics Market Set to Witness Significant Growth - openPR
Scaling the genomics lab for the data deluge - Illumina
Illumina CIO Carissa Rollins to retire in April By Investing.com - Investing.com Australia
Illumina CIO Carissa Rollins to retire in April - Investing.com
Interrogating challenging genomic regions provides new answers for patients - Illumina
Unlocking a world of complete biological understanding - Illumina
Is Illumina, Inc. (ILMN) the Best Diagnostics Stock to Invest in Right Now? - Insider Monkey
Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain? - Yahoo Finance
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):